Conserved Genetic Networks Define Er-Alpha Status And Luminal And Basal Phenotypes In Mouse And Human Mammary Cancer: Added Value From The Mouse

aleksandra m michalowska,tinghu qiu,claudine kavanaugh,eva y h p lee,daniel medina,xiaoling xu,chuxia deng,john i powell,joanna h shih,jeffrey e green

IF: 11.2

2006-01-01

Cancer Research

Abstract:1551 Defining molecular similarities and differences between genetically engineered mouse models of mammary cancer and human breast cancer is critical to the further understanding of molecular mechanisms of oncogenesis and identifying models most relevant to human disease. One goal of this study was to use expression profiling in an attempt to determine whether several important, oncogenic pathway specific mouse models of mammary cancer could be classified according to the basal - luminal distinctions identified for human breast cancer. We demonstrate that all of the models studied in which p53 is mutated or functionally impaired and a BRCA1 mutant model cluster with human tumors in the basal-type category. All models in which the myc, ras, her2/neu and Polyoma middle T-antigen are driven by the MMTV promoter share molecular characteristics that cluster them with human luminal-type breast tumors. Interestingly, these models have been shown to lack ER-alpha expression (which is strongly associated with lack of GATA-3 expression in human breast cancers), but high expression of transcription factor GATA-3 is observed in our data for these models. A third group of mouse tumors include ER+ tumors arising from the p53fp/fp;Wap- cre model, which cluster with ER+ human tumors representing the luminal type A group. This new classification of GEM models provides a rational approach for further investigating the cellular origins of the different tumor classes and the appropriate use of the models in relation to the human tumor subclasses, especially pre-clinical testing. A second objective of this study was to determine whether mouse and human breast cancers share gene signatures based upon the status of ER expression. We have performed the first supervised comparison of gene expression profiles from mouse ER+ and ER- mammary tumors (generated by the mammary-specific conditional knock-out mutation of the p53 gene) with that of ER+ and ER- human breast tumors. Direct integration of gene expression levels from mouse tumors with that from human tumors (based upon ER expression) resulted in the most accurate classifier for ER status in human breast cancer, demonstrating the important added value of mouse data generated in a well-defined genetic background. The mouse-human ER classifier represents a set of genes co-expressed between mouse and human and can be placed into evolutionarily conserved networks based upon estrogen signaling. This approach reveals functionally conserved genes and networks across species important for cancer biology and identifying potential new therapeutic targets.